~ Chennai is fourth in the row after the Sputnik V pilot soft launch in Fortis Gurgaon, Mohali and Jaipur
~ Around 70 people vaccinated on Day 1 of the rollout
Chennai, July 12, 2021: Today, leading hospital chain Fortis Healthcare rolled out Sputnik V as a part of a pilot soft launch, the third vaccine approved for India, for the general public at Fortis Hospital Vadapalani. Around 70 number of people got Sputnik V on the day 1 of the rollout and registration for the vaccination can be done through the COWIN and Aarogya Setu applications. The vaccine stock has been directly procured by Fortis, from Dr. Reddy’s Laboratories, as per Government guidelines and has been priced at Rs. 1,145 (as per government guidelines – inclusive of administrative charges).
While Fortis Hospital Vadapalani continues to administer COVISHIELD AND COVAXIN, Sputnik V is also being made available to the public. Recent trials have shown that Sputnik V, has an efficacy of over 90% and will bring down symptomatic Covid-19 cases by over 90%, making it possible for India’s large population to be safe from infection from future virus strains.[1] Fortis Healthcare ramped up its vaccination drive since April 2021 when vaccines were opened to all age groups above 18.
Dr. Sanjay Pandey, Zonal Director, Fortis Hospital Vadapalani, said, “we are happy to see the interest among general public to get themselves vaccinated. This indicates that the misconceptions on COVID vaccines is evading and people are getting confident on vaccine. Fortis is actively working towards ensuring that as many Indians as possible are fully vaccinated. Till date, our unit was only providing COVAXIN and COVISHIELD, however, we are pleased to announce that Fortis Hospital Vadapalani, in collaboration with Dr. Reddy’s Laboratories, providing the third vaccine option, with the dual objective of expanding and scaling up the vaccination drive and lowering the infection risks to future mutations of the virus. We urge all the eligible citizens to get vaccinated to ensure safe India. It is essential.”
As a part of the phase wise pilot project, the two-dose vaccine has been successfully introduced by Fortis Healthcare at Fortis Hospital, Vadapalani.
About Fortis Healthcare
Fortis Healthcare Limited – an IHH Healthcare Group Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organizations in the country with 36 healthcare facilities (including projects under development), 4000 operational beds, and over 400 diagnostics centres (including JVs). Fortis is present in India, United Arab Emirates (UAE) & Sri Lanka. The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with global major and parent company, IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs 23,000 people (including SRL) who share its vision of becoming the world’s most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.
[1] https://www.firstpost.com/health/russias-sputnik-v-vaccine-has-91-6-efficacy-against-covid-19-says-study-based-on-phase-3-trials-9265281.html